미국 · 보도자료 · CRISPR Therapeutics AG · 2026-10-08 12:30
미국심장협회(AHA)서 크리스퍼 유전자치료제 임상 공개
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ® , its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American
CRISPR Therapeutics AG 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
